Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss	$ (67,251)	$ (122,380)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	74,137	79,315
Non-cash interest	12,753	2,057
Amortization of debt issuance cost	1,328	908
Losses from investments in investees	7	99
Equity-based compensation – employees and non-employees	7,983	8,746
Realized loss (gain) on disposal of fixed assets and sales of equity securities	(9,489)	1,444
Change in fair value of equity securities and derivative instruments	(94,626)	14,406
Loss on conversion convertible senior notes	725	0
Contingent consideration	0	(1,023)
Deferred income tax (benefit) provision	7,695	7,307
Gain on sale of assets	(121,493)	0
Changes in assets and liabilities:
Accounts receivable, net	15,680	8,741
Inventory, net	6,452	4,082
Other current assets and prepaid expenses	(8,395)	10,220
Other assets	564	(2,666)
Accounts payable	(6,527)	191
Foreign currency measurement	(3,575)	24
Accrued expenses and other liabilities	44,952	(1,374)
Net cash (used in) provided by operating activities	(139,080)	10,097
Cash flows from investing activities:
Investments in investees	0	(5,000)
Proceeds from sale of equity securities	46,731	364
Purchase of marketable securities	(1,454)	0
Proceeds from the sale of property, plant and equipment	169	1,109
Capital expenditures	(19,597)	(13,253)
Proceeds from LabCorp Sale	210,378	0
Net cash provided by (used in) investing activities	236,227	(16,780)
Cash flows from financing activities:
Issuance of 3.00% convertible senior notes, net (including related parties)	230,000	0
Issuance of 2044 Notes	250,000	0
Issuance of 3.75% 2029 convertible notes, debt issuance cost	(13,385)	0
Share repurchase	(73,759)	0
Proceeds from the exercise of common stock options	(208)	(273)
Repurchase of 2029 Convertible Notes	(4,881)	0
Borrowings on lines of credit	448,459	515,318
Repayments of lines of credit	(465,301)	(519,597)
Redemption of 2025 Notes and 2033 Senior Notes	(146,287)	(3,000)
Net cash provided by (used in) financing activities	224,638	(7,552)
Effect of exchange rate changes on cash, cash equivalents and restricted cash	2,399	(335)
Net decrease in cash, cash equivalents and restricted cash	324,184	(14,570)
Cash, cash equivalents and restricted cash at beginning of period	95,881	153,191
Cash, cash equivalents and restricted cash at end of period	420,065	138,621
SUPPLEMENTAL INFORMATION:
Interest paid	12,982	10,748
Income taxes paid, net of refunds	3,801	(823)
Assets acquired by finance leases	0	713
Operating lease right-of-use assets in exchange for lease obligations	0	5,966
Non-cash financing:
Common stock options, warrants, and restricted stock units surrendered in net exercise	208	301
Fair value of shares received related to milestone achieved from GeneDx Holdings	$ 0	$ 6,689